Aerovance inhales $38M for asthma drugs
Aerovance, developer of asthma medications, just brought in $38 million in a post-recapitalized third round of funding to push its lead drug candidate through a second phase of clinical trials. The company has already received $20 million, with the option of claiming the remaining $18 million as necessary.
Based in Berkeley, Calif., the company has already seen its drug, Aerovant, through the first part of second-phase trials. The company will use the new money to complete the phase and refine its manufacturing processes. While Aerovance has a drug used to treat eczema in the pipeline, it said it will look for a partner to help fund its development rather than diverting money from this round of capital.
ProQuest Investments led the round, which also included BB Biotech Ventures, Alta Partners, Apax Partners, Burrill & Co., Clarus Ventures, Lehman Brothers Healthcare Fund and NGN Capital. In March of last year, Aerovance took in $10 million in debt financing from Comerica Bank, Oxford Finance and Silicon Valley Bank.
Next Story: FriendFeed’s redesign has given them something to talk about
Previous Story: Roundup: Aggregated links to newspaper web sites, and more
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.